In Alzheimer's disease, Novartis has just launched a cholinergic esterase inhibitor. It is hoped that future approaches will address the degenerative process within Alzheimer's. In Parkinson's disease, the approach is similar. Pharmaceutical research at Novartis laboratories Molecular biology and genomics are very hot at the moment. Novartis supports a considerable amount of genomic research externally.
Genomic research is more descriptional than functional at the moment.
The trick is to be ready when the anticipated flood of functional information is loosed. That is, the better the research, the better the job prospects. A second crucial aspect is networking. It's important to have good connections with colleagues to tap into the latest insights right away. An expert in the field of European Careers in Biotechnology and Pharmaceuticals will be our guest October 15 - November 17.